Bringing Transformational Medicines to Patients through Innovation

We are passionate about creating transformational therapies through innovation to address unmet medical needs in oncology for patients worldwide.

Corporate Presentation

Find out more

Innovation in 3 Generations

Monoclonal Antibody

Lemzoparlimab CD47
Uliledlimab CD73

Bi-Specific Antibody

TJ-CD4B Claudin 18.2 x 4-1BB
TJ-L14B PD-L1 x 4 -1BB

Super Antibody

mRNA, Probody
AI Design, Alphabody

Monoclonal Antibody

Lemzoparlimab CD47
Uliledlimab CD73

Bi-Specific Antibody

TJ-CD4B Claudin 18.2 x 4-1BB
TJ-L14B PD-L1 x 4 -1BB

Super Antibody

mRNA, Probody
AI Design, Alphabody

Latest News

Press Releases

2022.07.22

I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China

I-Mab today announced that the first patient in China has been treated with TJ-CD4B in a Phase 1 IMCT for patients with solid tumors.

2022.07.18

I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022

I-Mab today announced that it will present the latest Phase 2 clinical data of lemzoparlimab in combination with azacitidine in patients with higher risk myelodysplastic syndrome as a proffered paper at 2022 ESMO Congress.

2022.07.06

I-Mab to Host 2022 R&D Day

I-Mab today announced that it will host its 2022 Research and Development Day on July 20, 2022.

Highlights

  • 20

    Innovative Assets

  • 15

    Late Stage Clinical Trials

  • 300+

    Issued Patents &
    Patent Applications

  • 60%

    Employees with
    Advanced Degrees

  • ~ $800M

    Partnerships Cash Stream
    in Five Years

Our Transformative Journey

Founded

I-Mab was established in June 2016

Series A Financing

I-Mab completed Series A financing, raising $10 million

Merger & Series B Financing

Third Venture Biopharma and Tasgen merged to form I-Mab, raising $150 million in Series B Financing

Series C Financing

I-Mab successfully raised $220 million in Series C Financing

Nasdaq Listing

I-Mab was listed on the Nasdaq Global Market as a clinical-stage biotech company

AbbVie Global Partnership

I-Mab and AbbVie enter into global strategic partnership on development and commercialization of I-Mab's novel CD47 monoclonal antibody lemzoparlimab

Private Placement with Hillhouse Capital-Led Consortium

I-Mab entered into $418 million private placement agreement with Hillhouse Capital-led consortium

Global Footprint

I-Mab established its global footprint with 9 locations, including new R&D site in San Diego, and new GMP facility in Hangzhou

Jumpcan Partnership

I-Mab and Jumpcan entered into a strategic partnership for commercialization of I-Mab’s highly differentiated long-acting recombinant human growth hormone, eftansomatropin alfa in mainland China

Moving Forward Together

At I-Mab, we are tackling the most challenging scientific problems

Our People

“Clinical researchers are real life superheroes providing innovative treatments to those in need.”

I-Mab Employee

“I'm inspired by my colleagues' dedication to excellence in the work that we do; their kindness and care make it easy to work together on challenging projects.”

I-Mab Employee

“At I-Mab, gender inclusivity is not a tagline. The Company provides various platforms for female employees to flourish. We feel much supported in our personal and career development.”

I-Mab Employee